Search

Displaying results 281 - 290 of 7673 in total
  1. Drug

    Opipramol

    go.drugbank.com/drugs/DB12930
    Investigational

    Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

    Products: INSIDON 100MG FTA, OPIPRAMOL FARMA 50MG FTA
  2. Drug

    Methylene blue

    go.drugbank.com/drugs/DB09241
    ApprovedInvestigational

    Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. … clinical trials to be an inhibitor of Tau protein aggregation.

    Mixtures: Urin D/S, Prosed/DSSynonyms: Azul de metileno, Cloruro de metiltioninio
  3. Drug

    Amlodipine

    go.drugbank.com/drugs/DB00381
    ApprovedInvestigational

    The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label]. … Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than

    Mixtures: ARAHKOR DUO, LODESTAR-DUOProducts: NORVASC 5MG FTA, AMLODIPINO DE 5MG
  4. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    [A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip … Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus.

    Products: GLUCOTROL XL TABLETAS DE 20MG
  5. Drug

    Ondansetron

    go.drugbank.com/drugs/DB00904
    ApprovedInvestigationalWithdrawn

    [L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation. … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.

    Products: Ran-ondansetron, Van-ondansetron
  6. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery

    Products: DEXOPRAL ® 60 CAPSULA DE LIBERACIÓN RETARDADA, DEXOPRAL ® 30 CAPSULA DE LIBERACIÓN RETARDADA
  7. Drug

    Kaolin

    go.drugbank.com/drugs/DB01575
    Approved

    Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was ...

    Products: Dr Pore Tightening PINK CLAY FACIAL MASK, Dr Pore Tightening GLACIAL CLAY FACIAL MASK
  8. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A174463] Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent.[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

    Products: SUTRILNEO 5 MG COMPRIMIDOS DE LIBERACIÓN PROLONGADA, SUTRILNEO 10 MG COMPRIMIDOS DE LIBERACION PROLONGADA
  9. Drug

    Hydrotalcite

    go.drugbank.com/drugs/DB13322
    ApprovedInvestigationalWithdrawn

    Products: ALKA - SELTZER RA REGULADOR DE ACIDEZ - SUSPENSION, ALKA SELTZER RA REGULADOR DE ACIDEZ TABLETAS MASTICABLES
  10. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH.

    Products: TALMANCO 20MG FTA, TADALAFIL AOP 20MG FTA